[Importance of vitamin D in prostatic carcinoma].
BACKGROUND
Vitamin D has an antiproliferative effect on carcinomatous cells of the prostate. Vitamin D deficiency is considered a risk factor for the manifestation and development of prostate cancer. The authors present a report on plasma levels of vitamin D metabolites in patients with prostate cancer and vitamin D therapy is discussed.


RESULTS
In 14 patients with prostate carcinoma plasma concentrations of the sum of hydroxylated vitamin D metabolites and 1.25-dihydroxy vitamin D were assessed before treatment and three months after treatment. For evaluation of the sum of hydroxylated metabolites the radiotest was used; the plasma concentration of 1.25-dihydroxyvitamin D was assessed by radioimmunoanalysis. For statistical evaluation Friedman's test and simultaneous testing were used.


CONCLUSIONS
Vitamin D deficiency was not revealed, however, after 3 months treatment a mild vitamin D deficiency was manifested. In 28.5% of the patients very low levels of the sum of hydroxylated vitamin D metabolites and higher values of the specific prostatic antigen (PSA) persisted.
Wilczek
H
H
III. interní klinika 1. LF UK a VFN, Praha.
Vachalovský
D000368:Aged; D000369:Aged, 80 and over; D002118:Calcium / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood* / Q000150:complications / Q000628:therapy; D014807:Vitamin D / Q000097:blood*; D014808:Vitamin D Deficiency / Q000150:complications
D010710:Phosphates; D014807:Vitamin D; D002118:Calcium